Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | DRD1 | P21728 | 1/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.49 |
| ▸ | SCN1A | P35498 | 1/20 | 0.49 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.49 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11028792 | 0.90 | HTT (0.54) | HTTCA2ADRA2AADRA1AHTR1A | |
| SCHEMBL407408 | 0.83 | ADRA2A (0.51) | HTTCA2ADRA2AADRA1AHTR1A | |
| SCHEMBL8788249 | 0.77 | HTT (0.61) | HTTCA2ADRA2AADRA1AHTR1A | |
| SCHEMBL12309752 | 0.77 | POLB (0.62) | HTTCA2ADRA2AADRA1AHTR1A | |
| SCHEMBL1545537 | 0.77 | HTT (0.66) | HTTCA2ADRA2AADRA1AHTR1A | |
| SCHEMBL1568393 | 0.77 | HTT (0.66) | HTTCA2ADRA2AADRA1AHTR1A | |
| SCHEMBL5871673 | 0.77 | HTT (0.61) | HTTCA2ADRA2AADRA1AHTR1A | |
| SCHEMBL406531 | 0.77 | HTT (0.61) | HTTCA2ADRA2AADRA1AHTR1A | |
| SCHEMBL11484814 | 0.77 | ADRA2A (0.56) | HTTCA2ADRA2AADRA1AHTR1A | |
| SCHEMBL8425913 | 0.77 | HRH3 (0.43) | CA2ADRA2AHTR1AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6602903-B2 | Substituted O- and/or S heterocyclic compounds; powerful ligands for melatoninergic receptors. | LES LABORATORIES SERVIER (FR) | 2003-08-05 | — | — | US | disclosed |
| US-20020052400-A1 | Substituted heterocyclic compounds | ADIR ET COMPAGNIE | 2002-05-02 | — | — | US | disclosed |
| US-6313160-B1 | FOR THERAPY AND PROPHYLAXIS OF MELATONINERGIC DISORDERS | ADIR ET COMPAGNIE (FR) | 2001-11-06 | — | — | US | disclosed |
| EP-0998471-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING AND COMPOSITIONS CONTAINING SAME | ADIR ET COMPAGNIE (FR) | 2000-05-10 | — | — | EP | disclosed |
| WO-1998052935-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING AND COMPOSITIONS CONTAINING SAME | ADIR ET COMPAGNIE (FR) | 1998-11-26 | — | — | WO | disclosed |
| EP-0047531-B1 | 2-(1,4-BENZODIOXAN-2-YLALKYL) IMIDAZOLES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SYNTEX (U.S.A.) INC. (US) | 1985-06-12 | — | — | EP | disclosed |
| US-4497818-A | 2-(1,4-Benzodioxan-2-ylalkyl)imidazoles useful as antihypertensives and platelet aggregation inhibitors | SYNTEX (U.S.A.) INC. (US) | 1985-02-05 | — | — | US | disclosed |
| US-4436914-A | ANTIDEPRESSANTS, ANTICOAGULANTS | SYNTEX (U.S.A.) IC., 3401 HILLVIEW AVE., P.O. BOX 10850 A CORP. OF DE | 1984-03-13 | — | — | US | disclosed |
| EP-0074711-A2 | Benzodioxane-imidazoline compounds, their preparation and use | SYNTEX (U.S.A.) INC. (US) | 1983-03-23 | — | — | EP | disclosed |
| WO-1982001874-A1 | 2-(1,4-BENZODOIOXAN-2-YLALKYL)IMIDAZOLES USEFUL AS ANTIDEPRESSANTS | SYNTEX INC (US) | 1982-06-10 | — | — | WO | disclosed |
| EP-0047531-A1 | 2-(1,4-Benzodioxan-2-ylalkyl) imidazoles, their preparation and pharmaceutical compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1982-03-17 | — | — | EP | disclosed |
| US-4315021-A | 2-(1,4-Benzodioxan-2-ylalkyl)imidazoles | SYNTEX (U.S.A.) INC. (US) | 1982-02-09 | — | — | US | disclosed |
| US-4302469-A | 2-(1,4-Benzodioxan-2-ylalkyl)imidazoles useful as antidepressants | SYNTEX (U.S.A.) INC. (US) | 1981-11-24 | — | — | US | disclosed |
| US-4301171-A | 2-(1,4-Benzodioxan-2-ylalkyl)benzimidazoles useful as anti-depressants | SYNTEX (U.S.A.) INC. (US) | 1981-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052400-A1 | Substituted heterocyclic compounds | MTNR1A, MTNR1B, CBR1 | HTT 1392/4885CA2 1662/4885ADRA2A 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.